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ABSTRACT 
 
 
Background: An intricate cross-talk connects Tissue Factor (TF) to inflammation and is 
amplified by locally active angiotensin(ang)II, that stimulates TF expression. High glucose 
may activate pro-inflammatory pathways and increase glucose-mediated angII production. 
Aim: To evaluate the effect of Renin Angiotensin System (RAS) blockade on TF 
expression in peripheral blood mononuclear cells (PBMCs) exposed to normal glucose 
(NG) and high glucose (HG), and stimulated by lipopolysaccharide (LPS), a well known 
pro-inflammatory agent.  
Methods: PBMCs, from healthy donors were LPS-stimulated and exposed to NG and HG. 
TF mRNA levels, antigen expression and pro-coagulant activity were assessed by Real 
Time-PCR, ELISA and 1-stage clotting assay respectively, in absence or presence of 
pharmacological intervention. 
Results: LPS stimulation increased TF expression in NG, an effect down-regulated by 
Aliskiren, a direct renin inhibitor, zofenopril, an angiotensin converting enzyme inhibitor, 
olmesartan, an angII type1 receptor (AT1R)  blocker and Compound21, an highly selective 
angII type 2 receptor (AT2R)  agonist. As compared with NG, HG amplified the LPS-
stimulation of TF expression, an effect that Aliskiren, Zofenopril and Compound21 down- 
regulated in HG with a similar behavior to that in NG, while OLM activity was potentiated 
in HG.  
Conclusions: Our data disclose tight connections between the apparently unrelated 
domains of innate immunity and metabolic and cardiovascular regulation, expanding the 
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restrictive view of angII as a peptide mainly involved in the control of blood pressure and 
water and salt homeostasis. 
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1. INTRODUCTION 
 
1.1 Tissue Factor (TF). 
 
Tissue factor (TF), also known as thromboplastin or CD142, is a glycosylated 
transmembrane protein consisting of a single polypeptide chain with a molecular weight of 
about 45 kDa [1]. The TF gene is located on chromosome 1 and consists of 6 exons [2]. 
After transcription of the TF gene F3, the primary TF transcript is processed on post-
transcriptional level [3, 4], which consequently leads to generation of two naturally 
occurring isoforms: membrane-bound “full-length” (fl)TF  and soluble “alternatively 
spliced” (as)TF [5, 6]. Due to alternative splicing the fifth exon of the primary TF 
transcript is excluded [6, 7] and translation of this messenger (m)RNA splice variant leads 
to the generation of asTF on protein level that lacks the transmembrane domain that is 
therefore soluble [6]. TF is the principal initiator of the clotting cascade and a major 
regulator of  haemostasis and thrombosis [8]. The coagulation cascade is initiated as soon 
as TF comes into contact with circulating activated factor VII (FVIIa), resulting in the TF-
FVIIa complex. The TF-VIIa complex activates factor IX, which in turn activates factor X; 
alternatively, factor X is directly converted to factor Xa by TF-FVIIa. In complex with 
factor Va and calcium (Ca
2+
), Factor Xa catalyzes the conversion of prothrombin to 
thrombin, thereby leading to fibrin formation, platelet activation, and, ultimately, 
generation of a thrombus. Beside its primary function as initiator of the blood coagulation 
cascade [6, 9, 10], flTF plays an important role in a variety of other biological processes, 
such as migration and proliferation of vascular smooth muscle cells (VSMCs) [11], 
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protease-activated receptor (PAR-)2-mediated cell signaling and tumor progression [9, 12, 
13].  
In the vessel wall, TF is constitutively expressed in sub-endothelial cells such as VSMCs 
leading to rapid initiation of coagulation when the vessel is damaged [14]. TF is also 
present in different pools that are in contact with the circulating blood: associated with 
endothelial cells, white cells and platelet [15], associated with cell-derived microparticles 
(MP)[16] and present in a soluble form lacking the transmembrane domain [6]. In contrast 
with sub-endothelial cells, endothelial cells and monocytes, that show very little to no 
basal expression of TF under physiological conditions, express TF in response to various 
stimuli. Endothelial TF is induced by cytokines such as tumor necrosis factor-α (TNF-
α)[17], interleukin(IL)-1β [18], or CD40 ligand [19], by biogenic amines such as serotonin 
[20] and by mediators such as thrombin, oxidized LDL, or vascular endothelial growth 
factor (VEGF) [21-23]. In monocytes TF expression can be induced by inflammatory 
stimuli such as C-reactive protein [24] or CD40 ligand [25], platelet-derived growth 
factor(PDGF)-BB, angiotensin(ang)II, oxidized LDL [26, 27] and endotoxin 
(lipopolysaccharide, LPS) [28, 29].  
1.2 TF role in thrombosis. 
 
TF expression by endothelial cells and monocytes following inflammatory stimuli 
contribute to the development of acute thrombotic events. TF activity is significantly 
higher in the lesions present in patients with unstable angina or myocardial infarction, 
compared to patients with a stable form of angina [30, 31]. The antigen levels of TF in 
plasma is associated with an increased risk of death from cardiovascular causes [32] and 
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with an increase in the thickness of the carotid intima-media, considered a marker of 
atherosclerosis [33]. Acute coronary patients have higher levels of TF bound to monocytes 
[34], and of circulating TF [35, 36] compared to patients with stable angina and normal 
subjects, suggesting a potential release of TF at the level of the coronary artery during the 
acute ischemia. Pathological studies have identified TF, present in the atherosclerotic 
plaque, as a candidate molecule responsible for the thrombogenicity associated with plaque 
rupture [37]. Monocytes infiltrate the intimal layer and then transform into macrophages 
and foam cells, which represents a hallmark of the inflammatory nature of atherosclerosis 
[38]. In this inflammatory environment, cytokines such as TNF-α and  ILs are released and 
induce expression of TF. During the early stages of atherogenesis, enhanced TF expression 
is observed in monocytes [14]; at later stages, TF expression is also detected in foam cells, 
endothelial cells, and VSMCs [14, 39]. TF is present in the necrotic core of plaques as 
well, predominantly associated with microparticles derived from perishing foam cells, 
macrophages, or lymphocytes [39, 40]. Lipid-rich plaques with a thin cap, a large lipid 
core, extensive macrophage infiltration, and abundant TF expression are more prone to 
rupture than collagen-rich, fibrous plaques. Rupture of an atherosclerotic plaque exposes 
its highly procoagulant content to the circulating blood; thereby, TF-laden macrophages as 
well as TF-containing microparticles originating from the necrotic core initiate thrombus 
formation and related complications leading acute myocardial infarction (MI) but also to 
those that characterize the course of hypertension [41]. 
1.3 Bidirectional relation between Inflammation and TF. 
 
Inflammation and coagulation play pivotal roles in the pathogenesis of vascular disease. 
Increasing evidence points to extensive cross-talk between these two systems, that closely 
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interact: coagulation considerably affects inflammatory activity and inflammation leads to 
activation of coagulation. Coagulation factors may activate PARs of which 4 types (PAR 1 
to 4) have been identified, all belonging to the family of transmembrane domain, G-
protein–coupled receptors expressed on mononuclear cells or endothelial cells [42], which 
may affect, for example, cytokine production or inflammatory cell apoptosis. Thrombin 
binds PARs 1, 3, and 4 and induces the production of several cytokines and growth factors, 
whereas PAR-2 can be activated by the TF-factor VIIa complex, resulting in a up-
regulation of inflammatory responses in macrophages (production of reactive oxygen 
species and cell adhesion molecules) and affect neutrophil infiltration and pro-
inflammatory cytokine expression (e.g. TNF-α, IL-1β)  [43]. On the other hand activation 
of coagulation and fibrin deposition as a consequence of inflammation is well known and 
can be viewed as an essential part of the host defense of the body against, for example, 
infectious agents or non identical cells, in an effort to contain the invading entity and the 
consequent inflammatory response to a limited area. An exaggerated or insufficiently 
controlled response may, however, lead to a situation in which coagulation and thrombosis 
contribute to disease, as illustrated by the fact that thrombus formation on a ruptured 
atherosclerotic plaque, containing abundant inflammatory cells, is the pathological basis of 
acute arterial thrombotic events such as MI or unstable angina [44]. Expression of TF by 
inflammatory cells and probably due to sustained exposure to pro-inflammatory factors, 
such as IL-6,  PDGF and monocyte chemoattractant protein (MCP)-1 in the unstable 
plaque may initiate activation of coagulation, and the thrombin generated will both activate 
platelets and result in the formation of a platelet-fibrin thrombus [45]. Blocking TF activity 
completely abrogates inflammation-induced coagulation activation in models of 
experimental endotoxemia or bacteremia, whereas antibodies that inhibit the contact 
system have no effect on thrombin formation [46, 47].  
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1.4 NF-kB and Induction of TF expression by pro-inflammatory stimuli. 
 
Pro-inflammatory agents such as TNF-α and LPS are able to induce the synthesis of TF by 
the activation of nuclear transcription factor NF-kB [48]. NF-kB is a protein that controls 
networks of chemokine modulating, growth factor–modulating, translational control, and 
cellular survival genes [49]. NF-kB is a family of highly inducible DNA-binding proteins 
that consists of a group of dimeric complexes of members of the Rel protein family of 
which the p50-p65 eterodimer is the most common. In resting cells, NF-kB proteins are 
found mainly in the cytoplasm and form a complex with with a family of cytoplasmic 
inhibitors I-kBs, after cellular activation IκB is phosphorylated and degraded, allowing the 
transfer of NF-kB into the nucleus, where it binds to specific recognition sequences of 
target genes that code for pro-inflammatory and pro-atherogenic proteins [50]. The 
promoter of TF gene is partially under the control of NF-kB [28].  
 
1.5 Angiotensin II as a modulator of TF expression. 
 
Several studies have linked angiotensin(ang)II, the main effector of the renin-angiotensin 
aldosterone system (RAAS), to the synthesis of TF. A growing body of evidence gathered 
over the past several years has shown the wide ranging pro-thrombotic and pro-coagulant 
potential of angII including platelet sensitization, inhibition of fibrinolysis by PAI-1 
stimulation and activation of TF expression [51]. Notably, TF modulation may occur 
locally by activation of a local RAS contained within the monocytes/macrophages complex 
in atherosclerotic plaques. AngII influences the expression of pro-inflammatory molecules 
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with mechanisms that overlap those typical of the pro-inflammatory cytokines, such as 
TNF-α [52, 53] activating NF-kB. The binding of angII to angII type 1 receptor (AT1R) 
induces the activation of NF-kB and the increase of synthesis of TF in monocytes [26, 54], 
as well as in aortic endothelial cells of rat [55], and in VSMCs [56].  
Furthermore the inhibition of RAS in vitro induces a decrease of the expression of TF [26, 
57-60]. 
 
1.6 Renin Angiotensin Aldosterone System. 
 
The RAAS is a peptidergic system with endocrine characteristics which regulates the 
circulatory homeostasis. The system, present in most animal species, consists of several 
elements able to increase their circulating levels in response to the reduction in 
intravascular volume and to the decrease in renal perfusion pressure [61]. RAAS  
maintains blood pressure and body fluid volume homeostasis through arteriolar 
vasoconstriction, increased sympathetic activity and tubular Na
+
 reabsorption and 
stimulation of aldosterone release from the adrenal cortex [62].  
The substrate of the system, angiotensinogen, is an α-glycoprotein of high molecular 
weight, released from the liver [63] that is cleaved of the N-terminal portion in the 
circulation by the enzyme renin to form the decapeptide angiotensin(ang)I. Renin is 
synthesized by the cells juxtaglomerular (JG) of the kidney as a pre-pro-hormone, pro-
renin, which is converted to renin by proteolytic removal of a peptide segment of 43-amino 
acids in its N-terminal portion. The renin secretion is stimulated by a fall in perfusion 
pressure or decrease in the transport of NaCl and by an increased activity of the 
sympathetic nervous system. Renin secretion and activity represents the rate-limiting step 
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of the RAAS [64-67]. The inactive decapeptide angI is hydrolyzed by angiotensin-
converting enzyme (ACE), which removes the C-terminal dipeptide to form the 
octapeptide angII [Ang-(1-8)], a biologically active, potent vasoconstrictor. ACE is a 
membrane-bound exopeptidase and is localized on the plasma membranes of various cell 
types, including vascular endothelial cells, microvillar brush border epithelial cells (e.g., 
renal proximal tubule cells), and neuroepithelial cells [67]. AngII is the primary effector of 
a variety of RAAS-induced physiological and pathophysiological actions. At least 4 
angiotensin receptor subtypes have been described. The angII type 1 receptor (AT1R) 
mediates most of the established physiological and pathophysiological effects of angII. 
These include actions on the cardiovascular system (vasoconstriction, increased blood 
pressure, increased cardiac contractility, vascular and cardiac hypertrophy), kidney (renal 
tubular sodium reabsorption, inhibition of renin release), sympathetic nervous system, and 
adrenal cortex (stimulation of aldosterone synthesis) [67, 68]. The AT1 receptor also 
mediates effects of angII on cell growth and proliferation, inflammatory responses, and 
oxidative stress [68, 69]. This receptor, which is typical of the G protein-coupled receptor 
superfamily containing 7 membrane-spanning sequences, is widely distributed on many 
cell types in angII target organs. The angII type 2 receptor (AT2R) is abundant during 
fetal life in the brain, kidney, and other sites, and its levels decrease markedly in the 
postnatal period. There is some evidence that, despite low levels of expression in the adult, 
the AT2Rs, whose activation tends to counteract the biological effects of AT1R-mediated 
responses, might mediate vasodilation and anti-proliferative, anti-inflammatory and 
apoptotic effects and inhibit growth and remodeling in the heart [68, 70-76]. In the kidney, 
it has been proposed that activation of AT2R may influence proximal tubule sodium 
reabsorption [67, 69, 77]. The angII type 4 receptor (AT4R) are thought to mediate the 
release of plasminogen activator inhibitor 1 by angII and by the N-terminal truncated 
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peptides (angIII and angIV), but the function of the angII type 3 receptor (AT3R) is 
unknown [67].  
 
1.7 Intracellular Renin Angiotensin System. 
 
One of the most significant advancements in the past two decades has been the discovery 
of local or tissue RASs [78, 79]. The intracellular RAS is characterized by the presence of 
its components inside the cell and synthesis of angII at an intracellular site. The primary 
nature of RAS components, such as the presence of signal peptides in AGT and renin, and 
the transmembrane nature of ACE, is generally thought not to be supportive of an 
intracellular system. However, the existence of differentially glycosylated isoforms of 
AGT [80, 81], alternatively spliced forms of renin [82, 83], intracellular and secreted forms 
of ACE [84], alternative angII-generating enzymes (such as cathepsins and chymase) [85, 
86], and detection of these components intracellularly, under certain cellular conditions 
[84, 87], support the hypothesis of an intracellular RAS. In addition to its intracellular 
presence or synthesis, angII should be able to mediate biological effects from an 
intracellular location, to be functionally relevant. Local systems are regulated 
independently of the circulatory RAS but can also interact with the latter and have been 
demonstrated in heart [88, 89], in kidneys [90], in brain [91], in pancreas [92], and 
reproductive [78], lymphatic [78], and adipose tissues [93].  
Growing evidence also showed the cytokine-like potential of locally-synthesized angII to 
act in a paracrine, autocrine and possibly intracrine manner to promote endothelial 
dysfunction and vascular inflammation, two main components of the atherogenic process 
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[94, 95]. Regarding this aspect, an intracellular RAS is present in monocytes, a cellular 
population capable of generating the whole set of RAS components, including renin, 
angiotensinogen, ACE and angII [96-99] and endowed with AT1Rs [100] and AT2Rs 
[101].  
 
1.8 High glucose-induced intracellular synthesis of angII. 
 
RAS activation plays a relevant role in diabetes [102], a prothrombotic state [103] to which 
elevated glucose, the disease hallmark, may contribute by activating pro-inflammatory 
pathways [104-106] and increasing the cellular content of RAS components [87, 107-109]. 
In particular, in a study on rat mesangial cells, high glucose resulted in a time-dependent 
increase in the expression of the genes encoding prorenin, AGT, ACE and cathepsin B. 
The increase in renin activity was accompanied by a several-fold increase in intracellular 
angII concentrations, which localized predominantly in the nucleus [87]. In human renal 
mesangial cells, angII levels increased only in cell lysates, and not in the medium, 
following high-glucose exposure [110]. In another study, intracellular angII synthesis was 
studied in Neonatal Rat Ventricular Myocytes (NRVMs), in response to elevated glucose 
levels. Receptor-mediated internalization of angII was prevented by an AT1 receptor 
blocker (candesartan) in the cellular medium. High glucose-induced intracellular angII 
synthesis was accompanied by increased intracellular retention and decreased extracellular 
levels of AGT and renin, consistent with intracellular angII generation. Additional 
experiments, using specific enzyme inhibitors, determined that renin and chymase, but not 
ACE, were responsible for high glucose-induced intracellular angII synthesis [111].  
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1.9 RAS Pharmacological inhibition. 
 
Different clinical strategies have been developed for inhibiting the RAAS.  
β-Blockers. In 1970, Laragh and colleagues have shown that in hypertensive patients, 
therapy with β-blockers (propanolol) reduced of about 75% plasma levels of renin as 
blocking the release of renin beta-1-mediated by the kidney. In addition to the suppression 
of renin release, there is evidence that the β-adrenergic receptor blockade may inhibit the 
conversion of intrarenal prorenina in renin [66, 112]. 
ACE Inhibitors (ACEIs). ACEIs block the action of ACE, and thus the conversion of 
angI to angII. The reduction of angII levels causes a dose-dependent reduction of cardiac 
preload and after-load, with a drop in systolic blood pressure and diastolic, while in 
normotensive and hypertensive patients without cardiac dysfunction, it causes little or no 
change in cardiac output and capillary pressure [113]. ACEIs also decrease renal vascular 
resistance, determine increase in renal blood flow and promote the excretion of water and 
sodium. 
AT1R Blockers (ARBs). ARBs act by antagonizing the angII effects mediated by AT1R, 
reducing systemic blood pressure by decreasing systemic vascular resistance [114]. 
Direct Renin Inhibitors (DRIs). DRIs are the newest class of agents that block RAS and 
recently they have been approved for the treatment of hypertension. They block renin 
catalytic activity, the RAS initial step [115]. 
– Aliskiren Aliskiren, potent renin inhibitor, is the first nonpeptide to be approved by 
the FDA and EMEA for the treatment of hypertension. It is given either as a single 
agent and in combination with other antihypertensive agents. It is a highly 
lipophilic molecule that improves its oral bioavailability [115]. Subsequent studies 
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in normotensive subjects have demonstrated an efficient RAS blockade with 
Aliskiren [116, 117].  
AT2R agonists. The AT2R activation tends to counteract the biological effects of AT1R-
mediated responses including their pro-inflammatory potential [68, 70, 71, 73, 74, 118]. 
However, experimental verification of that hypothesis has been delayed by the absence of 
specific AT2R agonists, as previous studies addressing that issue [119] had only to rely 
upon pharmacological AT2R blockade, an approach encumbered by several conceptual 
and methodological pitfalls [76, 120].  
– Compound (C) 21 is a recently synthesized, highly selective AT2R agonist [121]. 
The specificity of the response of the compound C21 was evaluated in relation to 
those induced by angII in mechanisms in which it has a AT2R direct stimulation. 
C21 is able to induce neurite outgrowth in vitro with a similar effect to that angII 
mediated, an effect inhibited by the AT2R antagonist PD123,319. In vivo C21 
increases in a concentration-dependent manner the alkaline duodenal secretion, an 
effect inhibited, also in this case, by the AT2R antagonist [121]. In rats in which 
was induced MI, C21-dependent AT2R stimulation decreases the synthesis of 
various pro-inflammatory cytokines such as IL-6, IL-2, as well as the inhibition, in 
the peri-infarct area, of caspase 3 and Fas-Ligand expression indicating an anti-
apoptotic effect C21-mediated [122]. The anti-inflammatory effects modulated by 
C21 are confirmed also in endothelial cells and human fibroblasts, where it has 
been demonstrated that AT2R stimulation inhibits NF-kB, with consequent 
reduction of pro-inflammatory cytokines expression [123]. 
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1.10 RAS Pharmacological inhibition and TF modulation. 
 
Inhibition of the RAS downregulates TF expression in numerous experimental models. In 
vitro experiments with monocytes isolated from normal volunteers have shown that 
preincubation of LPS-stimulated monocytes with the ACE inhibitor, captopril, caused a 
significant reduction of TF activity, TF mRNA, and NF-kB translocation into the nuclei. 
Fosinopril and idrapril showed similar effects [59]. Blocking the RAS downstream, with 
the AT1R blocker Losartan, also inhibited TF activity in the same model [59] and 
prevented the upregulation of TF mRNA synthesis by rat aortic endothelial cells [55]. 
Similar results were obtained by He and colleagues, who showed that human peripheral 
blood monocytes cultured in the presence of angII express a procoagulant activity identical 
to TF, as well as TF mRNA, an effect inhibited by Losartan, an AT1R  antagonist [38]. Del 
Fiorentino and colleagues have reported that blocking the RAS with the ACE inhibitor 
zofenopril, with the AT1R blockers olmesartan and with the direct renin inhibitor, 
aliskiren, inhibited TF synthesis and function in TNF-α stimulated human umbilical vein 
endothelial cells [58]. Valsartan-treated transgenic rats overexpressing the human renin 
and angiotensin genes showed inhibited NF-kB activation and TF synthesis as compared 
with placebo controls [124]. The role of RAS inhibition in TF synthesis was also 
investigated in humans. Three different AT1R blockers, losartan, irbesartan, and 
candesartan, or placebo, were administered to 122 hypertensive patients for 2 months. All 
treatments, as expected, caused a significant reduction of blood pressure, with no 
difference among them. TF activity was measured at the beginning and at the end of the 
study period; all treatments reduced TF activity with different potencies 
(candesartan>irbesartan>losartan) [125]. In coronary artery disease patients has observed a 
decreased circulating TF activity after treatment with enalapril, an ACE inhibitor [36]. 
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2. AIMS 
 
 
The aims of this work were twofold. First, to evaluate the effect of RAS inhibition, with 
aliskiren (ALI), a direct renin inhibitor (DRI), zofenopril (ZOF), an ACE inhibitor (ACEI), 
olmesartan (OLM), an AT1R blocker (ARB) and Compound(C)21, an highly selective 
AT2R agonist on TF expression in Peripheral Blood Mononuclear Cells (PBMCs) exposed 
to LPS, the principal glycolipid component of the outer membrane of Gram-negative 
bacteria and a well characterized inflammatory stimulus signalling through the redox-
sensitive NF-kB pathway. 
Second, to evaluate the effect of increasing glucose concentrations on TF expression in 
PBMCs exposed to LPS and in that experimental setting to investigate the modulating 
potential of RAS blockade on the antigenic and functional expression of LPS-induced TF.  
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3. MATERIALS AND METHODS 
 
3.1 Cell isolation and culture. 
 
Peripheral blood mononuclear cells (PBMCs) were obtained from unpooled buffy coats 
left over from blood bank draws taken from healthy donors, with the approval of the local 
ethics committee. According to local procedures, individuals with a history of 
hypertension, either on antihypertensive drugs or not, are excluded from blood donation. 
As detailed elsewhere [126], leukocytes were isolated from fresh buffy coats diluted 1:1 
with sodium citrate 0.38% in saline solution, mixed gently with 0.5 volume of 2% Dextran 
T500 and left for 40 min for erythrocyte sedimentation. The leukocyte-rich supernatant 
was recovered and centrifuged for 10 min at 200xg. The pellet was resuspended in 30 ml 
of sodium citrate solution, layered over 15 ml of Ficoll-Hypaque and centrifuged for 30 
min at 350xg at 20°C. The PBMC-rich ring was recovered, washed twice in sodium citrate 
0.38% and resuspended in no glucose RPMI 1640 medium (Sigma Chemical, St Louis, 
Missouri, USA) supplemented with 100 U/ml penicillin-streptomycin. The final PBMC 
preparations typically contain 25–35% monocytes, 65–75% lymphocytes and less than 5% 
neutrophils [126].  
After isolation, cells resuspended in polypropylene tubes (3x10
6
 cells/ml) were exposed to 
experimental drugs or their appropriate vehicle in presence of different D-glucose 
concentrations (5.5 mM, heretofore referred to as Normal Glucose, NG, or 50 mM 
heretofore referred to as High Glucose, HG) or equivalent amounts of L-Glucose as a 
control for osmolarity 30 min prior to LPS (Escherichia coli 026:B6 LPS; Sigma 
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Chemical), 0.1 μg/mL, and left to incubate for 18 hs at 37°C in a 5% CO2 atmosphere until 
assay.  
PBMCs incubated without either LPS or drugs were also included to obtain baseline 
values. All reagents and solutions used for cell isolation and culture were prepared with 
endotoxin-free water and glassware was rendered endotoxin-free by exposure to high 
temperature. Drugs were kept in stock solution and diluted in serum-free RPMI at the 
appropriate concentrations immediately before use. Cell viability as assessed by dimethyl 
thiazolyl diphenyl tetrazolium (MTT) was verified (85% or more of viable cells) 
throughout all experimental phases. 
 
3.2 TF pro-coagulant activity (PCA). 
 
PCA was assessed by a one-stage clotting time test in PBMCs disrupted by three freeze–
thaw cycles, as previously described [126]. In brief, disrupted cells (100 ml) were mixed 
with 100 ml of normal human plasma at 37°C, adding 100 ml of 25 mmol/l CaCl2 at 37°C. 
Time to clot formation was recorded and values converted to arbitrary units (AU) by 
comparison with a human brain TF calibration curve covering clotting times from 20 to 
600 s, corresponding to 1000 and 0 AU, respectively. Experiments were run in triplicate 
and averaged. As contaminating platelets (typically less than 1 platelet/PBMC) may 
contribute to PCA [127], we performed the clotting assay in PBMC-free preparations in 
preliminary experiments containing a comparable number of platelets. PCA under these 
conditions was undetectable. 
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3.3 TF antigen (ag). 
 
Cells were disrupted by three repeated freeze–thaw cycles and debris pelleted by 
centrifugation at 100xg for 1 h at 4°C and supernatants used for ELISA (Imubind TF kit 
Sekisui Diagnostics, West Malling, United Kingdom). Briefly, 100 ml of the TF standards 
or the supernatant samples were incubated overnight at 4°C in microwells precoated with a 
murine antihuman TF capture antibody. The captured TF was detected using a biotinylated 
antibody fragment. Then, binding of streptavidin-conjugated horseradish peroxidase (HRP) 
completed the formation of the antibody–enzyme detection complex, and the addition of 
tetramethylbenzidine substrate and its subsequent reaction with the HRP created a blue 
coloured solution. The sensitivity of the method was increased by the addition of 0.5 mol/l 
sulfuric acid stop solution, which yielded a yellow colour. Solution absorbances were 
measured in a microplate reader at 450 nm. TF ag levels were expressed in pg/ml using a 
reference curve created by the TF standards. Within and between assay variability was 3.5 
and 5.5%, respectively. 
 
3.4 TF mRNA. 
 
Total RNA was extracted from PBMCs using the Rneasy mini kit (Qiagen). RNA 
concentration and purity were determined by optical density measurement via Nanodrop 
(Thermo Fisher Scientific, Wilmington, Delaware USA). A mixture of 0.5 ng total RNA 
per sample was retro-transcribed with random primer-oligodT into complementary DNA 
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(cDNA) using the Quantitect Reverse Transcription Kit (Qiagen, Hilden, Germany). The 
retro-transcription cycle was performed at 25°C for 5 min, 42°C for 30 min and 95°C for 3 
min. RealTime-PCR was carried out in a iQ5 Real Time PCR System and SsoAdvanced 
Sybr Green Supermix (Bio-Rad Laboratories, Hercules, CA) was employed on the basis of 
the manufacturer’s instructions with a final reaction of 20 µl. RealTime-PCR was 
performed under the following conditions: 95°C, 30s; 40 cycles 95°C, 5s, 60°C, 15s;a final 
melting protocol with ramping from 65°C to 95°C with 0,5°C increments of 5sec was 
performed. The primers sequence for realtime-PCR were: TF, sense 5’-
TTGGCAAGGACTTAATTTATACAC-3’, antisense 5’-CTGTTCGGGAGGGAATCAC-
3’; GAPDH, sense: 5’-CCCTTCATTGACCTCAACTACATG-3’ and antisense: 5’-
TGGGATTTCCATTGATGACAAGC-3’ (Sigma-Aldrich, St. Louis, MO). All samples 
were analysed in duplicate and averaged. The relative expression of the target gene was 
normalized to the level of GAPDH in the same cdna. 
 
3.5 Experimental Design. 
3.5.1  Effect of RAS Blockers on LPS-induced TF ag expression and PCA. 
 
Aliskiren (ALI), a direct renin inhibitor (DRI)[128], zofenopril (ZOF), an angiotensin 
converting enzyme inhibitor (ACEI)[129], olmesartan (OLM)[130], an angII type 1 
receptor blocker (ARB) or vehicle were added at log-increasing (10
−11–10−6 M) steps to 
PBMCs LPS-stimulated (0.1 μg/mL) under NG conditions to delineate the profile of the 
respective inhibitory concentration-response curves.  
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In additional series, PCA was characterized by adding an antihuman TF antibody (30 
μg/mL, 30 minutes), which neutralizes the procoagulant activity of both TF and TF/FVIIa 
complexes (affinity purified inhibitory goat anti-human-TF IgG, epitope-specific for amino 
acid sequence 1-25, American Diagnostica), to suspensions of LPS-stimulated PBMCs 
under either HG or NG conditions. 
3.5.2  Effect of AT2R agonism and antagonism on LPS-induced TF expression. 
 
To establish the effect of C21, a specific AT2R agonist [121], on TF ag and PCA and 
delineate its concentration–response profile, LPS-stimulated PBMCs were exposed at log-
increasing drug concentrations (10
-8–10-5 M). To assess the effect of C21 on TF 
transcription, levels were quantified in LPS-stimulated PBMCs in absence or presence of 
maximally effective drug concentrations (10
-5
 M). To validate the underlying assumption 
of AT2R agonism by C21, additional experiments were run in LPS-stimulated PBMCs 
preincubated with maximally effective concentrations of PD123,319 or OLM (10
-6
 M for 
both). 
To evaluate, also, the effect of AT2R blockade per se on TF ag and PCA and delineate its 
concentration–response profile, LPS-stimulated PBMCs were exposed at log-increasing 
concentrations PD123,319 (di(trifluoroacetate) salt hydrate, Sigma, Milan, Italy, 10
-11–10-6 
M), an AT2R antagonist [131]. 
3.5.3 Effect of Glucose on TF expression. 
 
To evaluate the effect of glucose on TF expression, LPS-stimulated PBMCs were exposed 
to four increasing concentrations of D-Glucose (5.5, heretofore referred to as normal 
glucose, NG, 16.5, 26 and 50 mM) using L-Glucose as a control for osmolarity changes. 
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The effect of 50 mM D-glucose (the concentration achieving the maximum effect, 
heretofore referred to as HG) on TF expression was then compared to NG in PBMCs 
activated by LPS.  
3.5.4  Effect of AT2R agonism and AT1R blockade  on LPS-induced TF expression in 
PBMCs exposed to HG. 
 
To assess the effect of AT2R agonism and AT1R blockade on LPS-induced TF expression 
under HG conditions, C21 or OLM were added at log-increasing (10
-8
-10
-5
 M) steps to 
LPS-stimulated PBMCs with NG as a control.  
3.5.5 Effect of AT2R agonism in AT2R-blocked PBMCs exposed to HG. 
 
To evaluate the C21 AT2R specificity, C21 was added at log-increasing (10
-8
-10
-5
 M) steps 
to LPS-stimulated PBMCs exposed to NG or HG, after a pre-incubation of 30 minutes with 
PD123,319 (10
-6
 M, , Sigma Milan, Italy), a specific AT2R antagonist. 
3.5.6 Effect of angII on LPS-induced TF PCA under NG and HG conditions. 
               
To assess the assumption of the involvement of locally expressed angII in our system, 
angII was tested in PBMCs exposed to NG or HG.  
3.5.7 Effect of NF-kB inhibition on LPS-induced TF PCA under NG and HG 
conditions.    
 
To test the involvement of NF-kB in our system,  BAY 11-7082 (10-5 M Sigma, Milan, 
Italy), a well characterized inhibitor of NF-kB [132], the key controller of TF gene 
expression [8], was added in LPS-stimulated PBMCs exposed to NG and HG. 
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3.5 Statistics 
 
Mann Whitney test for unpaired data and Wilcoxon test for paired data were used on 
absolute data or percent changes from control conditions. Data were reported as means±SD 
unless otherwise reported. A two-tailed p-level <0.05 was the threshold for statistical 
significance. 
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4. RESULTS 
 
LPS stimulation (0.1 μg/mL) increased TF PCA (from 0.0054±0.0033 to 0.93±0.36 AU, 
n=33, p<0.001), TF ag expression (from 32±24 to 1486±388 pg/mL, n=19, p<0.001) and 
TF mRNA (from 0.005±0.0027 to 0.65±0.5 normalized fold expression, n=8, 
p<0.001)(Fig.1 panels a,b,c respectively). 
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Fig.1. LPS stimulation (0.1 μg/mL) increased TF PCA (n=33, panel a), TF ag expression (n=19, panel b) and 
TF mRNA (n=8, panel c). *** p<0.001 
 
To LPS-stimulated PBMCs was added an anti-human TF antibody (30 μg/mL), which 
neutralizes the TF PCA (from 0.93±0.36 to 0,019±0,0095 AU, n=5, p<0.001) (Fig.2). 
                                    
bas
elin
e
g/m
L)

LPS
 (0.
1 
ant
i-hu
ma
n T
F a
ntib
ody
0.0
0.5
1.0
1.5 *** ***
P
C
A
(A
rb
it
ra
ry
 u
n
it
s
)
 
Fig. 2. The anti-human TF antibody (30 μg/mL) neutralizes the TF PCA LPS-stimulated (n=5). *** p<0.001  
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4.1 Effect of RAS Blockers on LPS-induced TF expression. 
 
ALI, ZOF and OLM downregulated LPS-activated TFAg expression and PCA to a 
comparable extent as regards maximum efficacy under NG conditions (TFAg: 
ALI:−44±6%, n=6, ZOF:−40±19%, n=6, OLM:−37±5%, n=5; PCA: ALI:−44±22%, n=11, 
ZOF:−52±15%, n=6, OLM:−48±18%, n=5, p<0.001 vs vehicle for all). However, 
inhibition by ALI achieved its peak at 10
−11
 M and decreased at higher drug 
concentrations, a pattern opposite to that of both ZOF and OLM (Fig. 3, left and right 
panels). 
 
Fig. 3. Decreasing inhibition of LPS-stimulated TFAg (left panel, n=6) and PCA (right panel, n=11) by 
ascending concentration of aliskiren vs the opposite behaviour of zofenopril and olmesartan. For the sake of 
clarity, figures report only mean values. * p<0.001 Aliskiren vs Zofenopril; & p<0.001 Aliskiren vs 
Olmesartan; ! p<0.05 or less vs 10
−11
 M values. 
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4.2 Effect of AT2R agonism and antagonism on LPS-induced TF 
expression.    
C21 downregulated in a concentration-dependent manner TFag and PCA, an effect 
antagonized by PD123,319 and left unchanged by OLM (Fig. 4, left and right).  
 
Fig.4. C21 downregulates lipopolysaccharide-stimulated tissue factor antigen (left, n=13) and PCA (right, 
n=14), an effect antagonized by PD123,319 (10
-6
 M, n=6 and 14, respectively) and left unchanged by OLM 
(10
-6
 M, n=7 and 10, respectively). For the sake of clarity, only mean values are reported. ! p<0.001 C21 vs. 
vehicle; * p<0.001 C21 vs. C21+PD123,319. 
 
C21 blunted LPS-induced TF mRNA (from 0.82±0.57 to 0.24±0.13 normalized fold 
expression, n=5 each, p<0.001), a 3.5-fold inhibition (Fig. 5). 
 
Fig.5. C21 (10-5 M) inhibits lipopolysaccharide-induced tissue factor mRNA stimulation. Mean±SD, n=5 
each; * p<0.001. 
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PD123,319 per se did not affect LPS-induced TF PCA and antigen expression (Fig. 6, left 
and right). 
10
-11
 M 10
-10
 M 10
-9
 M 10
-8
 M 10
-7
 M 10
-6
 M
-40
-20
0
PCA
D
e
c
re
a
s
e
 %
 f
ro
m
 t
h
e
 v
e
h
ic
le
10
-11
 M 10
-10
 M 10
-9
 M 10
-8
 M 10
-7
 M 10
-6
 M
-40
-20
0
TF ag expression
D
e
c
re
a
s
e
 %
 f
ro
m
 t
h
e
 v
e
h
ic
le
 
Fig.6. PD123,319 effect on lipopolysaccharide-stimulated TF PCA (right, n=11) and ag expression (left, 
n=7). For the sake of clarity, only mean values are reported.  
 
 
4.3 Effect of Glucose on TF expression.   
 
Increasing D-glucose up to a 50 mM concentration augmented LPS-induced PCA without 
evidence of a plateau. Equimolar L-glucose concentrations were neutral (Fig. 7).  
 
Fig. 7. Increasing D-Glucose concentrations (black bars) augment LPS (100 ng/mL)-induced PCA as 
opposed to the ineffectiveness of L-glucose (gray bars). Mean±SD, n=11; * p<0.001 vs 5.5 nM, & p<0.001 
vs 26 nM, £ p<0.001 vs 16.5 nM, NS=Not significant vs 5.5 nM.         
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As compared with NG, HG amplified the stimulatory effect of LPS also on TF ag (from 
1486±388 to 2652±622 pg/mL, n=19, p<0.001) and TF mRNA (from 0.65±0.5 to 
0.85±0.53 normalized fold expression, n=8, p<0.01) (Fig. 8, panels a and b, respectively). 
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Fig.8. HG amplified the stimulatory effect of LPS on TF ag (n=19, panel a) and TF mRNA (n=8, panel b) 
*** p<0.001, ** p<0.01 
 
4.4 Effect of AT2R agonism and AT1R blockade on LPS-induced TF 
expression in PBMCs exposed to HG.      
      
C21 down-regulated in a concentration dependent manner LPS-induced TF PCA without 
differences between NG and HG (Fig.9, panel a) while the concentration dependent 
inhibitory effect of OLM was greater in HG than in NG (Fig.9, panel b). Similar data were 
obtained evaluating TF ag and TF mRNA (Fig.10, panel a and panel b respectively).      
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Fig. 9. C21 downregulated in a concentration dependent manner LPS-induced TF PCA in NG maintaining 
unchanged its effect in HG (panel a, n=12). Figures report mean±SD, *** p<0.001, ** p<0.01 vs. vehicle in 
NG, ! p<0.001 vs. vehicle in HG. OLM downregulated in a concentration dependent manner LPS-induced TF 
PCA in NG potentiating its effect in HG (panel b, n=12). ** p<0.01, * p<0.05 OLM in HG vs. OLM in NG, ! 
p<0.001 vs. vehicle in NG, $  p<0.001 vs. vehicle in HG.   
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Fig.10. C21 and OLM downregulated LPS-induced TF ag (panel a, n=7) and TF mRNA (panel b, n=8) in 
NG. OLM inhibitory effect on TF ag and TF mRNA was potenziated in HG (panel a and panel b 
respectively). Figures report mean±SD. ! p<0.05, !!! p<0.001 vs. vehicle in NG; $$ p<0.01, $$$ p<0.001 vs. 
vehicle in HG; * p<0.05, *** p<0.001 OLM in HG vs. OLM in NG 
 
4.5 Effect of AT2R agonism in AT2R-blocked PBMCs exposed to HG.  
   
The pre-treatment with PD123,319 (10
-6
 M) inhibited C21 downregulation of LPS-induced 
TF PCA in NG and in HG (Fig.11) demonstrating AT2R specificity of these effects also 
under HG conditions. These results has also been confirmed with TF ag (Fig.12). 
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Fig.11. The pre-treatment with PD123,319 (10
-6
 M) inhibited C21 effect in NG and in HG (left panel and 
right panel, respectively)(n=6) Figures report mean±SD. ** p<0.01, * p<0.05 vs. C21+ PD123,319.  
-80
-60
-40
-20
0
20
40
NG
HG
C21 10-5 M C21+
PD123,319 10-6 M
d
e
c
re
a
s
e
 %
 f
ro
m
 t
h
e
 v
e
h
ic
le
 
Fig.12. The pre-treatment with PD123,319 (10
-6
 M) inhibited C21 effect in NG and in HG (left panel and 
right panel, respectively)(n=6) Figures report mean±SD. ** p<0.01, * p<0.05 vs. C21+ PD123,319. (NG: 
3±15%, n=6, p<0.001 vs C21 alone; HG:  9±30%, n=6, p<0.001 vs C21 alone) 
  
4.6 Effect of angII on LPS-induced TF PCA under NG and HG 
conditions.   
     
AngII (10
-6 
M) stimulated TF PCA in NG (from 0,005±0,002 to 0,01±0,006 AU, n=14, 
p<0.01) and in HG (from 0,011± 0,007 to 0,02± 0,01 AU, n=10, p<0.05), an effect 
inhibited by OLM (10
-6 
M)(NG: 10
-6 
M -38±17%, n=4, p<0.01; HG: 10
-6
 M -59±3%, n=4, 
p<0.001)(Fig.13).  
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Fig.13. AngII (10
-6
 M) stimulated TF PCA in NG (n=14) and in HG (n=10), an effect inhibited by OLM (10
-6 
M) in NG and in HG (n=4).  Figures report mean±SD. *** p<0.001, ** p<0.01, * p<0.05  
 
                
 4.7 Effect of NF-kB inhibition on LPS-induced TF PCA under NG and 
HG conditions.    
 
BAY 11-7082, a NF-kB inhibitor, abolished at a 10
-5
 M concentration the LPS-stimulated 
PCA in PBMCs exposed to NG or HG (NG: -95±3%, n=8, p<0.001; HG: -99±0.3%, n=8, 
p<0.001). 
 
 
Fig. 14. BAY 11-7082, a NF-kB inhibitor (10
-5
 M) abolished the LPS-stimulated PCA in PBMCs exposed to 
NG and HG (n=8). Figures report mean±SD. *** p<0.001  
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5. DISCUSSION 
 
 
Our results highlight the ability of the RAS and in particular of its main effector, angII, to 
modulate the expression of TF in monocytes a cellular population capable of generating 
the whole set of RAS components: angII [99], renin [96], angiotensinogen [98], ACE [97], 
angII receptors [100, 101]. The antagonism of LPS-stimulated TF expression by a highly 
heterogeneous group of drugs such as ALI, ZOF, OLM sharing angII blockade as the only 
common pharmacological denominator, confirms the involvement of the RAS in the TLR-
4 signalling pathway reported by others in different experimental conditions [133]. In 
addition, our data provide original evidence suggestive of endotoxin-mediated activation of 
the upstream and rate-limiting step of the system since TF inhibition by ALI, a direct renin 
inhibitor, was maximal at concentrations (10
−11
 M) coincident with those inhibiting the 
interaction of human renin with its substrate angiotensinogen (6×10
−12
 M)[128]. The 
peculiar inhibitory concentration-response relationship of ALI, characterized by fading 
efficacy as a function of increasing drug concentrations, a trend opposite to that elicited by 
ZOF and OLM opens obvious but unanswered questions about mechanisms although 
unrestrained renin production as a reaction to a disrupted angII-mediated negative feed-
back by ALI may plausibly facilitate its binding to newly identified (pro)renin 
receptor((P)RR)s [134] and promote the synthesis of counteracting pro-thrombotic 
mediators independent of the classical pathways operated by angII [135]. 
Moreover, we document for the first time the inhibitory potential of AT2R stimulation on 
inflammation-mediated pro-coagulant response by down-regulating TF expression. In 
particular TF mRNA down-regulation by C21 likely reflects NF-kB inhibition, a crucial 
controlling step in gene transcription in response to inflammatory agonists [8], consistent 
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with previous reports obtained in different experimental systems with C21 itself [123] and 
other AT2R agonists [118]. Inhibition by C21 of IL-6 production in TNF-α stimulated 
human and murine dermal fibroblasts [123] and primary rat astrocytes exposed to LPS 
[136] and reduced expression of inflammatory mediators in experimental models of 
myocardial and renal damage [122, 137, 138] as well as the additional evidence reviewed 
in detail elsewhere [76, 136] strengthen our conclusions. An obvious question raised by 
these results considers the reasons for the discrepancy between the inhibition induced by 
AT2R stimulation and the missing response to AT2R antagonism, this latter an already 
reported behaviour [119] for which several explanations might be envisaged. In fact, 
despite their predominance in foetal life, AT2R number decrease after birth and AT1Rs 
overcome the quantitative distribution of the other subset in adulthood by several fold 
[120]. Therefore, studies with the AT2R antagonist PD123,319 are easily bound to produce 
negative or equivocal results, as it is difficult to antagonise biological effects whose 
baseline functional expression is negligible [120]. As a matter of fact, unchanged levels of 
AT2R mRNA in inflamed human glomerular endothelial cells [119] suggest that the effect 
of C21 might represent the result of a pharmacological manipulation of physiologically 
silent binding sites exposed to an agonist attaining concentrations at the receptor site far 
exceeding those achieved by angII, the endogenous ligand [76, 136]. Other possible, not 
alternative explanations for the neutral effect of the AT2R antagonism may relate to the 
difficulty of eliciting some additional stimulation in an already stimulated system of which 
RAS activation is one of the several and interacting signalling pathways.  
Another relevant outcome of this study was the TF sensitivity of LPS-primed PBMCs to 
augmented ambient D-glucose, an effect independent of osmolarity changes and requiring 
cellular uptake and subsequent metabolism of the molecule, given the inefficacy of 
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equimolar concentrations of the impermeant L-isomer. RAS activation plays a relevant role 
in diabetes [102], a prothrombotic state [103] to which elevated glucose, the disease 
hallmark, may contribute by activating pro-inflammatory pathways [104-106] and  
increase glucose-mediated angII production reported by other authors in isolated cell 
systems exposed to HG [87, 107, 108]. The HG-dependent activation of 
inflammation/coagulation-related protein expression is due, at least partly, via increased 
oxidative stress [104]. Although not documented in our setting, the subsequent chain of 
intracellular events were likely to include, according to the available evidence, increased 
generation of reactive oxygen species (ROS) resulting from activation of NADPH oxidase 
and mitochondrial metabolism [106] acting as signalling molecules for NF-kB [104], a 
redox-sensitive transcription factor critical for the expression of genes encoding TF-
stimulating pro-inflammatory cytokine [105] and TF itself [8]. In accord with these data 
we observed that BAY 11-7082, a well characterized NF-kB inhibitor [132], completely 
abolished the pro-coagulant response to endotoxin, in normal and high glucose. The data 
are also coherent with previous reports of HG-induced overexpression of Toll-like 
receptor(TLR)4 [139] and CD14 [140], the LPS-receptor complex that, by recruiting 
adaptor proteins to the cytoplasmic Toll/interleukin-1 receptor domain, initiates a series of 
intracellular events leading to NF-kB activation [141]. In that complex chain of events 
RAS and TLR-4 are interconnected signalling pathways [57, 133, 142] making RAS 
activation an active part of the wide spectrum of biological responses finalized to defend 
the host from invading bacteria [141] and in which activation of the clotting cascade is a 
prominent part [44]. 
In the above delineated experimental context, C21, an AT2R agonist, modulated the 
expression of TF in NG [60] and its efficacy was unchanged by exposure to HG quite in 
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contrast with the enhanced response to OLM, an AT1R antagonist, an expected behavior 
explained by several, not alternative nor exhaustive mechanisms including increased 
glucose-mediated angII production [87, 108, 111], upregulated AT1R [143-146] or AT1R 
activation as a consequence of other mechanisms unrelated to receptor density or affinity 
[147].  
In conclusion, our results open insofar unexplored and potentially relevant facets to our 
understanding of the complex links connecting angII to inflammation ad coagulation and 
are useful to delineate more precisely the determinants of the atherothrombotic risk in 
diabetic patients [103]. Downregulation of responses finalized to defend the host from 
invading bacteria by blockade of a biological system pivotal to the onset and evolution of 
diabetes [102] and cardiovascular disease [100] discloses tight connections between the 
apparently unrelated domains of innate immunity and metabolic and cardiovascular 
regulation expanding the restrictive view of angII as a peptide mainly involved in the 
control of blood pressure and water and salt homeostasis. 
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ABBREVIATIONS 
 
 
ACE  Angiotensin Converting Enzyme  
ACEI  Angiotensin Converting Enzyme Inhibitor  
AGT  Angiotensinogeno 
ALI              Aliskiren 
ANOVA ANalysis Of VAriance  
ARBS Angiotensin II Receptor Blockers  
AS TF      Alternatively Spliced  Tissue Factor 
AT1R Angiotensin II Type 1 Receptor  
AT2R Angiotensin II Type 2 Receptor  
AT3R Angiotensin II Type 3 Receptor  
ATR4 Angiotensin II Type 4 Receptor  
DRI   Direct Renin Inhibitor  
ELISA Enzyme Linked Immuno-Sorbent Assay 
FL TF      Full-Length  Tissue Factor  
HG             High Glucose   
ICAM-1 Intercellular Adhesion Molecule 1  
I-kB  Inhibitor  of  Nuclear Factor κappa B  
  
58 
IL               Interleukin  
JG Juxtaglomerular Cells   
LPS Lipopolisaccaride  
MCP-1     Monocyte Chemoattractant Protein – 1 
MI                 Myocardial Infarction  
MP             Microparticles 
NF-kB  Nuclear Factor kB  
NG             Normal Glucose    
NO Nitric Oxide   
NRVMs Neonatal Rat Ventricular Myocytes  
OLM          Olmesartan 
PAR-1  Protease Activated Receptor 1  
PAR-2 Protease Activated Receptor 2  
PDGF Platelet Derived Growth Factor  
RAAS Renin Angiotensin Aldosterone System  
RAS Renin Angiotensin System  
SD Standard Deviation  
TF ag Tissue Factor Antigen  
TF PCA     Tissue Factor Pro-coagulant activity  
TF Tissue Factor  
  
59 
TGF-β Transforming Growth Factor βeta  
TNF-α Tumor Necrosis Factor-αlpha   
VCAM-1  Vascular Cell Adhesion Molecule 1  
VEGF Vascular Endothelial Growth Factor  
VSMCs Vascular Smooth Muscle Cells  
ZOF           Zofenopril 
